Skip to content

Biosimilars, Biologics, FDA Policy and Approvals, Clinical Trials, and Specialty Pharmacy

Home
- Home
About BR&R
Biosimilar Approval Status
BR&R Product Profiles
- Abrilada
- Amjevita
- Avasola
- Cyltezo
- Erelzi
- Eticovo
- Fulphila
- Hadlima
- Herzuma
- Hulio
- Hyrimoz
- Inflectra
- Kanjinti
- Mvasi
- Nivestym
- Nyvepria
- Ogivri
- Ontruzant
- Renflexis
- Retacrit
- Ruxience
- Trazimera
- Truxima
- Udenyca
- Zarxio
- Ziextenzo
- Zirabev
Contact Us
The 2021 Biosimilars Market Report

$0.00 0 items

video_2_edelbaum-mp4

October 8, 2018October 8, 2018

Published by

View all posts by

Published October 8, 2018October 8, 2018

Post navigation

Previous Post video_2_edelbaum-mp4

Leave a Reply Cancel reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

SM Health Comm

Search for:

Recent Posts

Biosimilar Bytes January 20, 2022
Samsung Bioepis Submits Supplemental Application for Citrate-Free, High-Concentration Adalimumab Biosimilar January 10, 2022
Second Insulin Biosimilar to Get FDA’s Nod—Eli Lilly’s Rezvoglar™ to Enter the Glargine Market December 24, 2021
Coherus Secures FDA Approval on Yusimry™, Its Adalimumab Biosimilar December 23, 2021
Sandoz Sends Trastuzumab Biosimilar Application to FDA December 21, 2021
Ustekinumab Biosimilars Update December 6, 2021
Biosimilar Bytes November 26, 2021
Amgen, Pfizer Now Seeking Adalimumab Interchangeability, but… November 16, 2021
What Do Patients Want to Know About Biosimilars? November 11, 2021
Progress on Coherus’ Pegfilgrastim On-Body Injector October 29, 2021

Recent Comments

	This Week in Biosimi… on Enticing Patients to Switch to…
	Biosimilar Bytes \| on A Profile on Lesser-Known Play…
	Samsung Bioepis Subm… on Further Dissecting the Launch…
	Pfizer's Adalim… on Momenta Signs Licensing Deal W…
	Limited Interest in… on Lilly to Launch Authorized Gen…

Archives

Archives

Meta

Log in
Entries feed
Comments feed
WordPress.org

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Email Address

Top Posts & Pages

Biosimilar Approval Status
The Evolution of the Biosimilars Market
Who Are the Key Aflibercept Biosimilar Players to Watch?
Second Insulin Biosimilar to Get FDA’s Nod—Eli Lilly’s Rezvoglar™ to Enter the Glargine Market
Who Are the Key Lucentis Biosimilar Players to Watch?
Biosimilar Bytes
The Next-Generation Biosimilar Race: A Tale of Two Autoimmune Biologics
Denosumab Biosimilar Competitors Gathering Data for February 2025 Launch
Ustekinumab Biosimilars Update
Hyrimoz

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookie Policy

Follow Us

Twitter
LinkedIn

Home
About BR&R
Biosimilar Approval Status
Contact Us
Terms and Conditions

Copyright

Copyright 2013-2022 by SM Health Communications. All Rights Reserved

Powered by WordPress.com.